211 related articles for article (PubMed ID: 25962692)
1. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
Zurawska U; Hicks LK; Woo G; Bell CM; Krahn M; Chan KK; Feld JJ
J Clin Oncol; 2012 Sep; 30(26):3167-73. PubMed ID: 22711851
[TBL] [Abstract][Full Text] [Related]
4. [A case of the usage of entecavir to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patient].
Muraoka T; Taira N; Shien T; Doihara H; Takaki A; Miyoshi S
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1861-4. PubMed ID: 22083198
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms.
Crespo J; Esteban R; Torres C; Oyagüez I; Casado MÁ; Buti M
Rev Esp Enferm Dig; 2017 Sep; 109(9):619-626. PubMed ID: 28648087
[TBL] [Abstract][Full Text] [Related]
6. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors.
Day FL; Karnon J; Rischin D
J Clin Oncol; 2011 Aug; 29(24):3270-7. PubMed ID: 21788556
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
11. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
[TBL] [Abstract][Full Text] [Related]
12. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.
Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C
PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer.
Ide Y; Ito Y; Takahashi S; Tokudome N; Kobayashi K; Sugihara T; Hattori M; Yokoyama M; Uchiyama A; Inoue K; Sakurai N; Hatake K
Breast Cancer; 2013 Oct; 20(4):367-70. PubMed ID: 20658270
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.
Hwang JP; Huang D; Vierling JM; Suarez-Almazor ME; Shih YT; Chavez-MacGregor M; Duan Z; Giordano SH; Hershman DL; Fisch MJ; Cantor SB
JCO Clin Cancer Inform; 2019 Mar; 3():1-12. PubMed ID: 30892921
[TBL] [Abstract][Full Text] [Related]
18. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
Kanwal F; Farid M; Martin P; Chen G; Gralnek IM; Dulai GS; Spiegel BM
Am J Gastroenterol; 2006 Sep; 101(9):2076-89. PubMed ID: 16968510
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for hepatitis C in Canada.
Wong WWL; Tu HA; Feld JJ; Wong T; Krahn M
CMAJ; 2015 Feb; 187(3):E110-E121. PubMed ID: 25583667
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
